|
Thomas W. D'Alonzo was appointed to our Board of Directors on August 30, 2006. Mr. D'Alonzo's experience in the biopharmaceutical industry spans more than 30 years as a top-level pharmaceutical executive, and includes all major facets of pharmaceutical operations. From 1983-1993, Mr. D'Alonzo worked at Glaxo, Inc., the U.S. subsidiary of the former Glaxo Holdings P.L.C., rising to the position of President of Glaxo from 1988-1993. At Glaxo he served on its board of directors and presided over 4,400 employees, including an 1,800 person sales force in a company that generated $3 billion dollars in annual revenues. Mr. D'Alonzo served as President and Chief Executive Officer of GenVec, Inc., a gene therapy biotechnology company. During his tenure at GenVec, two INDs were filed, Theragen, a separate gene therapy company, was acquired, and the company raised $20 million in funding. An attorney by training, Mr. D'Alonzo has also held corporate and general counsel positions at Hercules, Inc. and Adria Laboratories, Inc. He served as President and Chief Operating Officer of Pharmaceutical Product Development, Inc, a multi-national clinical research organization. At PPDI, he oversaw 3,000 employees in a company that generated $300 million in revenues. In 1999, Mr. D'Alonzo received his Honorary Doctor of Pharmacy from Campbell University, Buies Creek, North Carolina and has since served as a board member of other pharmaceutical companies, which currently includes, Salix Pharmaceuticals, Ltd., Amarillo Biosciences, Inc., and Dara Biosciences Inc. | 